[Urgent] Starlink Set For The Largest IPO In History?

He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000! And now, Elon could be set to do it for the third and final time… with what might be his biggest breakthrough yet. And for the first time ever, you have the rare chance to profit BEFORE the upcoming IPO.

Click here now for the urgent details on this hidden play.

Andreas Wicki Biography and Net Worth

Director of Pacira BioSciences

Dr. Wicki has served as a director since our inception in December 2006. Dr. Wicki is a life sciences entrepreneur and investor with over 20 years of experience in the pharmaceutical and biotechnology industries. Dr. Wicki has been Chief Executive Officer of HBM Healthcare Investments (Cayman) Ltd. (formerly HBM BioVentures AG) since 2001. From 1998 to 2001, Dr. Wicki was the Senior Vice President of European Analytical Operations at MDS Inc. From 1990 to 1998, he was co-owner and Chief Executive Officer of ANAWA Laboratorien AG and Clinserve AG, two life sciences contract research companies. From 2007 to 2011, he served as a member of the board of directors of PharmaSwiss SA. Previously, Dr. Wicki held board positions on several privately-held companies and companies listed on international exchanges. Dr. Wicki holds an M.Sc. and Ph.D. in chemistry and biochemistry from the University of Bern, Switzerland. He currently serves on the board of directors of Viela Bio, Inc. (Nasdaq: VIE), Buchler GmbH, Harmony Biosciences, Inc. (Nasdaq: HRMY), HBM Healthcare Investments (Cayman) Ltd., and HBM BioCapital Ltd.

What is Andreas Wicki's net worth?: The estimated net worth of Andreas Wicki is at least $35.66 million as of December 14th, 2022. Mr. Wicki owns 2,147,943 shares of Pacira BioSciences stock worth more than $35,655,854 as of November 17th. This net worth estimate does not reflect any other assets that Mr. Wicki may own. Learn More about Andreas Wicki's net worth.
How do I contact Andreas Wicki?: The corporate mailing address for Mr. Wicki and other Pacira BioSciences executives is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. Pacira BioSciences can also be reached via phone at (813) 553-6680 and via email at [email protected]. Learn More on Andreas Wicki's contact information.
Has Andreas Wicki been buying or selling shares of Pacira BioSciences?: Andreas Wicki has not been actively trading shares of Pacira BioSciences during the past quarter. Most recently, Andreas Wicki sold 10,601 shares of the business's stock in a transaction on Monday, March 15th. The shares were sold at an average price of $73.68, for a transaction totalling $781,081.68. Following the completion of the sale, the director now directly owns 5,242 shares of the company's stock, valued at $386,230.56. Learn More on Andreas Wicki's trading history.
Who are Pacira BioSciences' active insiders?: Pacira BioSciences' insider roster includes Donald Manning (Insider), Max Reinhardt (Insider), Charles Reinhart, III (CFO), Lauren Riker (VP), David Stack (CEO), Andreas Wicki (Director), Kristen Williams (Insider), and Roy Winston (Insider). Learn More on Pacira BioSciences' active insiders.
Are insiders buying or selling shares of Pacira BioSciences?: In the last twelve months, Pacira BioSciences insiders bought shares 3 times. They purchased a total of 11,176 shares worth more than $136,240.40. In the last twelve months, insiders at the sold shares 10 times. They sold a total of 113,661 shares worth more than $3,413,175.87. The most recent insider tranaction occured on September, 13th when COO Daryl Gaugler sold 500 shares worth more than $6,430.00. Insiders at Pacira BioSciences own 6.4% of the company. Learn More about insider trades at Pacira BioSciences.
Information on this page was last updated on 9/13/2024.

Andreas Wicki Insider Trading History at Pacira BioSciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/15/2021	Sell	10,601	$73.68	$781,081.68	5,242
3/11/2021	Sell	60,574	$72.70	$4,403,729.80
3/9/2021	Sell	35,137	$70.90	$2,491,213.30
9/9/2020	Sell	2,216	$62.02	$137,436.32
8/13/2020	Sell	34,904	$61.47	$2,145,548.88
8/11/2020	Sell	106,772	$61.32	$6,547,259.04
12/13/2018	Sell	14,527	$46.84	$680,444.68
11/16/2018	Sell	70,498	$47.34	$3,337,375.32
11/12/2018	Sell	5,478	$49.83	$272,968.74
11/9/2018	Sell	58,245	$51.11	$2,976,901.95
8/29/2014	Sell	21,494	$108.11	$2,323,716.34
8/27/2014	Sell	55,813	$108.08	$6,032,269.04
8/26/2014	Sell	24,207	$108.11	$2,617,018.77
8/25/2014	Sell	30,000	$108.07	$3,242,100.00
8/11/2014	Sell	150,000	$101.25	$15,187,500.00
6/6/2014	Sell	67,900	$82.62	$5,609,898.00
6/3/2014	Sell	68,000	$80.69	$5,486,920.00
5/27/2014	Sell	64,400	$77.93	$5,018,692.00
5/21/2014	Sell	3,600	$77.80	$280,080.00
5/8/2014	Sell	23,220	$75.76	$1,759,147.20
5/7/2014	Sell	44,780	$75.78	$3,393,428.40
3/6/2014	Sell	24,887	$80.16	$1,994,941.92
9/11/2013	Sell	17,783	$37.25	$662,416.75
7/22/2013	Sell	75,958	$35.06	$2,663,087.48
7/18/2013	Sell	25,560	$33.45	$854,982.00
7/16/2013	Sell	48,482	$33.28	$1,613,480.96
7/11/2013	Sell	80,000	$31.48	$2,518,400.00
7/5/2013	Sell	44,021	$30.80	$1,355,846.80
7/3/2013	Sell	114,448	$30.21	$3,457,474.08
6/19/2013	Sell	35,407	$29.90	$1,058,669.30
6/17/2013	Sell	50,145	$29.86	$1,497,329.70
6/12/2013	Sell	4,409	$30.00	$132,270.00
6/11/2013	Sell	11,500	$30.00	$345,000.00
6/5/2013	Sell	15,500	$30.26	$469,030.00
6/3/2013	Sell	1,900	$30.00	$57,000.00
5/22/2013	Sell	18,471	$30.00	$554,130.00
5/20/2013	Sell	14,374	$30.00	$431,220.00
3/25/2013	Sell	290,900	$27.95	$8,130,655.00

Andreas Wicki Buying and Selling Activity at Pacira BioSciences

Pacira BioSciences Company Overview

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.

Today's Range

Now: $16.60

$16.21

$16.66

50 Day Range

MA: $15.81

$12.73

$17.70

2 Week Range

Now: $16.60

$11.16

$35.95

Volume

780,465 shs

Average Volume

535,337 shs

Market Capitalization

$766.42 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.82